Inventor · disambiguated record
Claudia Ferrara Koller
Also filed as: FERRARA KOLLER CLAUDIA
19 granted patents·28 pending applications·189 citations·filing 2004–2025
94Inventor score
Files withHOFFMANN LA ROCHE35ROCHE GLYCART AG8BRUENKER PETER1GLYCART BIOTECHNOLOGY AG1HOFFMANN LA ROCHE INC1
Top patents by PatentIndex Score
47 records- 0197US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 0297US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 0397US10464981B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·33 cites·22 claims
- 0496US11718680B2Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonistsHOFFMANN LA ROCHE·Filed 2020·Granted Aug 8, 2023·5 cites·32 claims
- 0596US11447558B2Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9HOFFMANN LA ROCHE·Filed 2019·Granted Sep 20, 2022·14 cites·22 claims
- 0695US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 0795US11149083B2Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moietyHOFFMANN—LA ROCHE INC·Filed 2018·Granted Oct 19, 2021·12 cites·25 claims
- 0895US10526413B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2016·Granted Jan 7, 2020·23 cites·20 claims
- 0990US11214622B2Antibodies specific for DR5 and methods of useROCHE GLYCART AG·Filed 2018·Granted Jan 4, 2022·6 cites·13 claims
- 1090US9926379B2Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5ROCHE GLYCART AG·Filed 2014·Granted Mar 27, 2018·17 cites·28 claims
- 1188US2024301079A1Antigen binding molecules with increased fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 1287US9481730B2DR5—FAP bispecific death receptor agonistic antibodiesBRUENKER PETER·Filed 2010·Granted Nov 1, 2016·29 cites·9 claims
- 1387US2025101135A1Antigen binding molecules comprising a tnf family ligand trimerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1482US2025376523A1Humanized anti-human cd19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1581US2023212303A1Antigen binding molecules with increased fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 1680US12441812B2Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
- 1778US9296820B2Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector functionUMAÑA PABLO·Filed 2004·Granted Mar 29, 2016·8 cites·22 claims
- 1876US12215152B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Feb 4, 2025·0 cites·8 claims
- 1976US2025066448A1Her2-targeting antigen binding molecules comprising 4-1bblHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2075US12202870B2Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereofHOFFMANN LA ROCHE·Filed 2021·Granted Jan 21, 2025·0 cites·40 claims
- 2173US12227594B2Bispecific 2+1 contorsbodiesHOFFMANN LA ROCHE·Filed 2018·Granted Feb 18, 2025·1 cites·14 claims
- 2271US2021002382A1Antigen binding molecules with increased fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 2370US12240911B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2019·Granted Mar 4, 2025·0 cites·20 claims
- 2469US2023045262A1Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9HOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2568US2022073646A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2667US12065478B2HER2-targeting antigen binding molecules comprising 4-1BBLHOFFMANN LA ROCHE·Filed 2020·Granted Aug 20, 2024·0 cites·11 claims
- 2766US12281153B2Combination therapy with targeted 4-1BB (CD137) agonistsHOFFMANN LA ROCHE·Filed 2020·Granted Apr 22, 2025·0 cites·24 claims
- 2866US2020270321A1Antigen binding molecules comprising a trimeric tnf family ligandHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2963US2025340614A1Combination therapy with targeted 4-1bb (cd137) agonistsHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3061US2024043535A1IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULESHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3161US2023086210A14-1bbl trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3259US2022267464A1Fusion of an antibody binding cea and 4-1bblHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3358US2022025069A1Bispecific antigen binding molecules comprising lipocalin muteinsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3457US2019211113A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3556US2020325225A1Combination therapy with targeted 4-1bb (cd137) agonistsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3656US2016075793A1ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTIONROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 3756US2016075794A1ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTIONROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 3856US2016076009A1ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTIONROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 3955US2020317774A1Anti-human cd19 antibodies with high affinityHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4055US2018230215A1Anti-human cd19 antibodies with high affinityHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 4153US2021253724A1Novel bispecific agonistic 4-1bb antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4253US2021163617A1Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4352US2020347115A1Novel tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4451US2017247467A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4550US2022162295A1Method for the expression of an antibody-multimer-fusionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4648US2019016771A1Trimeric costimulatory tnf family ligand-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 4742US2007111281A1Antigen binding molecules having modified Fc regions and altered binding to Fc receptorsGLYCART BIOTECHNOLOGY AG·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Claudia Ferrara Koller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →